

**THE EFFECTS OF CHRONIC SUBCUTANEOUS
EXPOSURE TO LOW DOSE OF CHLORPYRIFOS ON
THE RAT KIDNEYS**

BY

SANDA AUNG

A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy (Medical Sciences)

**Kulliyyah of Medicine
International Islamic University Malaysia**

OCTOBER 2020

ABSTRACT

Introduction: Chlorpyrifos (CPF) is an organophosphate (OP) that is widely used as pesticide in agriculture. Epidemiological studies reported that the incidence of chronic kidney disease (CKD) of unknown cause was increasing among agricultural workers who were exposed to OPs during their working life through dermal contact. However, there is little information on the effects of chronic subcutaneous low dose of OP CPF on kidney in experimental animals. To date, the mechanism of OP-induced kidney damage is not fully elucidated. **Objective:** The aim of this study was to assess the effects of chronic subcutaneous low dose of OP CPF exposure on the kidney by investigating the structure and function of kidney and to assess the possible mechanisms of OP-induced kidney damage. **Methodology:** Eighteen male Sprague Dawley rats were randomly divided into three groups, with six rats in each group. Group 1 served as control group, while groups 2 and 3 received subcutaneous vehicle (3% dimethyl sulfoxide + 97% v/v soy oil) and CPF (18.0 mg/kg) respectively, every other day for 180 days. Blood was taken for biochemical analysis while kidney tissues were harvested for histology, immunohistochemistry (IHC) and selective gene expression. Cystatin C, acetylcholinesterase (AChE), advanced glycation end products (AGEs) and malondialdehyde (MDA) levels were measured using quantitative sandwich enzyme immunoassay. **Results:** Biochemical parameters (urea, creatinine, uric acid, glucose), cystatin C, AGEs and MDA levels were significantly increased ($p < 0.05$), while AChE activity and electrolytes levels were significantly decreased ($p < 0.05$) in the CPF-exposed rats. Structural damage of kidney, including diffuse global glomerular hypercellularity and diffuse necrosis of proximal tubular cells were observed in CPF-exposed kidney. IHC revealed strong immunostaining of polyclonal anti-AGEs in glomeruli and polyclonal anti-MDA in the proximal tubular cells of CPF-exposed rats. The expression of genes involved in glucose metabolism (*Ager*), oxidative stress (*Sod3*, *Cat*, *Gsr*, *Pon1* and *Nos2*) and cell death pathways (*Cyts*, *Casp3*, *Casp*, 8, *Casp*, 9, *Ripk1*, *Ripk3*, *Cst3*, *Havcr1* and *Lcn2*) showed downregulation trend. **Conclusion:** Chronic subcutaneous low dose of CPF caused renal dysfunction as evidence by increased endogenous glomerular filtration markers and reduced electrolytes levels and structural kidney damage. The downregulation of these genes could be due to selective exhaustion of pathways that were persistently activated during the prolonged chronic OP-mediated injury. In brief, chronic subcutaneous low dose of CPF caused nephrotoxicity. The process could be facilitated by the effects of CPF on glucose metabolism and oxidative stress.

خلاصة البحث

المقدمة: الكلوربيريفوس (CPF) هي فوسفات عضوية (OP) تستخدم على نطاق واسع كمبيد للآفات في الزراعة. أفادت الدراسات الوبائية أن معدل الإصابة بأمراض الكلى المزمنة (CKD) لسبب غير معروف يتزايد في أوساط العمال الزراعيين الذين تعرضوا للفوسفات العضوية أثناء حياتهم العملية من خلال ملامسة الجلد. ومع ذلك، هناك القليل من المعلومات حول آثار التعرض لجرعة منخفضة مزمنة تحت الجلد من الفوسفات العضوية من نوع الكلوربيريفوس على الكلى في الحيوانات التجريبية. حتى الآن، لم يتم توضيح آلية تلف الكلى الناتج عن الفوسفات العضوية. الهدف: كان الغرض من هذه الدراسة هو تقييم آثار التعرض لجرعة منخفضة مزمنة تحت الجلد من الفوسفات العضوية من نوع الكلوربيريفوس على الكلى من خلال فحص هيكل ووظيفة الكلى وتقييم الآليات المحتملة للتلف الكلوي الناجم عن الفوسفات العضوية. المنهجية: تم تقسيم ثمانية عشر ذكراً من فئران سراغ داوولي بشكل عشوائي إلى ثلاث مجموعات، بستة فئران في كل مجموعة. عملت المجموعة الأولى كمجموعة تحكم، في حين تلقت المجموعتان 2 و 3 حامل تحت جلدي من (3٪ داي ميثيل سلفوكسيد +97% حجم / حجم من زيت فول الصويا) و الكلوربيريفوس (18.0 ملغم / كغم) على التوالي، كل ثاني يوم لمدة 180 يوماً. ثم تم أخذ الدم للتحليل الكيميائي الحيوي في حين تم حصاد أنسجة الكلى من أجل اختبارات الأنسجة، و كيمياء الأنسجة المناعية (IHC) و التعبير الجيني الانتقائي. تم قياس مستوى السيستاتين C و الأستيل كولين إستريز (AChE) والمنتجات النهائية المتقدمة للجلوكوز (AGEs) و مستويات المالون داي ألدهايد (MDA) باستخدام التحليل الكمي المناعي الأنزيمي المنشطر. النتائج: كان هناك زيادة ذات دلالة ($p < 0.05$) في مستويات معاملات الكيمياء الحيوية (اليوريا، الكرياتينين، حمض اليوريك، الجلوكوز) و مستويات السيستاتين C و المنتجات النهائية المتقدمة للجلوكوز (AGEs) مستويات المالون داي ألدهايد (MDA) في حين انخفض مستوى الأستيل كولين إستريز (AChE) و مستويات الشوارد بمستويات ذات دلالة ($P < 0.05$) في الفئران المعرضة للكلوربيريفوس. وقد لوحظت الأضرار الهيكلية للكلى، بما في ذلك الزيادة الخلوية الكبيبية الشاملة المنتشرة و نخر منتشر في الخلايا الأنوبوية القريبة في الكلى المعرضة للكلوربيريفوس. كشفت كيمياء الأنسجة المناعية (IHC) تصبغات مناعية قوية في الجسم المضاد متعدد النسيلة للمنتجات النهائية المتقدمة للجلوكوز (AGEs) في الكبيبات و في الجسم المضاد متعدد النسيلة للمالون داي ألدهايد (MDA) في الخلايا الأنوبوية القريبة في الفئران المعرضة للكلوربيريفوس. أظهر التعبير عن الجينات المشاركة في استقلاب الجلوكوز (Ager) و التوتر التأكسدي (Sod3 و Cat و Gsr و Pon1 و Nos2) و مسارات موت الخلايا (Cycs و Casp3 و Casp8 و Casp9 و Ripk1 و Ripk3 و Cst3 و Havcr1 و Lcn2) اتجاه إنحفاضي. الخاتمة: تسببت الجرعة المنخفضة المزمنة تحت الجلد من الكلوربيريفوس في اختلال وظيفي كلوي بدليل زيادة علامات الترشيح الكبيبي الداخلية وانخفاض مستويات الشوارد وتلف الكلى الهيكلي. يمكن أن يكون سبب انخفاض هذه الجينات هو الاستنفاد الانتقائي للمسارات التي تم تنشيطها باستمرار أثناء الإصابات المزمنة عن طريق التعرض للفوسفات العضوية لفترة طويلة. باختصار، تسببت الجرعة المنخفضة المزمنة تحت الجلد من الكلوربيريفوس في السمية الكلوية. يمكن أن العملية قد تم تسهيلها من خلال تأثيرات الكلوربيريفوس على استقلاب الجلوكوز و على التوتر التأكسدي.

APPROVAL PAGE

The thesis of Sanda Aung has been approved by the following:

Norlelawati A. Talib
Supervisor

Nor Zamzila Abdullah
Co-Supervisor

Siti Aesah @ Naznin Muhammad
Internal Examiner

Md. Salzihan Md. Salleh
External Examiner

Nasir Mohamad
External Examiner

Tengku Haziya Amin Tengku Abdul Hamid
Chairperson


DECLARATION

I hereby declare that this thesis is the result of my own investigation, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Sanda Aung

Signature.....

Date



INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**EFFECTS OF EXPOSURE TO CHRONIC LOW DOSE OF
CHLORPYRIFOS ON THE RAT KIDNEYS**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright ©2020 Sanda Aung and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below.


1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

Affirmed by Sanda Aung

.....
Signature

.....
Date

*This thesis is dedicated to my parents for laying the foundation of what I turned out to
be in life.*



ACKNOWLEDGEMENT

Firstly, I would like to express my sincere gratitude to my advisor Prof. Tariq Bin Abdul Razak for the continuous support of my Ph.D study and related research, for his patience, motivation, and immense knowledge.

Besides, I would like to thank my supervisor Assoc. Prof. Dr. Norlelawati A Talib and co-supervisor Assoc. Prof. Dr. Nor Zamzila Bt. Abdullah for their guidance helped me in all the time of research and writing of this thesis, for their insightful comments and encouragement, but also for the discussion which incented me to widen my research from various perspectives.

I wish to acknowledge the help provided by the staff of Department of Basic Medical Science, Kulliyah of Pharmacy and Department of Pathology & Laboratory Medicine, Kulliyah of Medicine, International Islamic University Malaysia and Sr. Zamzuria Mat Zainone. Without their precious support it would not be possible to carry out this research.

My grateful thanks are also extended to Assoc. Prof. Dr. Nor Azlina A. Rahman from Kulliyah of Allied Health Science for statistical data analysis, to Dr. Norra Harun, Consultant Pathologist from Hospital Tengku Ampuan Afzan for examination of histology slides, to Dr. Abd Almonem Doolaanea from Kulliyah of Pharmacy for data analysis of biochemical results, to Dr. Wan Muhamad Salahudin from Kulliyah of Medicine for his useful thesis template and to Dr. Abd. Kareem M. Ahmed Al-Sahmi from Kulliyah of Pharmacy for translation of abstract to Arabic.

I would like to offer my special thanks to Prof. Noriah Bt. Mohd. Noor from Kulliyah of Pharmacy, who offered me an opportunity to study Ph.D, for her support and encouragement throughout my study.

I am grateful to the Ministry of Higher Education, Malaysia and Research Management Centre, International Islamic University Malaysia for the funding.

Last but not the least, I would like to thank my parents for supporting me spiritually throughout my study.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval page	iv
Declaration	v
Copyright	vi
Acknowledgement	viii
Table of Contents	ix
List of Tables	xiii
List of Figures	xiv
List of Abbreviations	xviii
CHAPTER ONE: INTRODUCTION	1
1.1 Justification of The Study	3
1.2 General Objective	3
1.3 Specific Objectives	3
CHAPTER TWO: LITERATURE REVIEW	5
2.1 Chlorpyrifos	5
2.1.1 Overview	5
2.1.2 History of Organophosphates and Chlorpyrifos Use	5
2.1.3 Toxicokinetic of Chlorpyrifos	6
2.1.4 Toxicodynamic of Chlorpyrifos	8
2.1.5 Organophosphates Poisoning	10
2.1.6 Effects of Organophosphates Exposure	11
2.1.7 Diagnosis of Organophosphates Exposure	14
2.2 Chronic Kidney Disease	15
2.2.1 Overview	15
2.2.2 Biomarkers of Kidney Damage	16
2.2.2.1 Urea	17
2.2.2.2 Creatinine	17
2.2.2.3 Cystatin C	18
2.2.2.4 Uric Acid	18
2.2.2.5 Kidney Injury Molecule-1	18
2.2.2.6 Neutrophil Gelatinase Associated Lipocalin	19
2.2.2.7 Monocyte Chemoattractant Protein-1	19
2.3 Chronic Kidney Disease and Organophosphate	20
2.3.1 Overview	20
2.3.2 Postulated Mechanisms of Organophosphates-induced Kidney Injury	21
2.3.2.1 Direct Kidney Injury	21
2.3.2.2 Hyperglycaemia and Advanced Glycation End-products	22
2.3.2.3 Low Paraoxonase-1 Activity	26
2.3.2.4 Oxidative Stress	26
2.4 Conceptual Framework	31

CHAPTER THREE: METHODOLOGY	32
3.1 Materials	32
3.1.1 Chemical and Reagents	32
3.1.1.1 Chemicals and Reagents Used for Animal Study.....	32
3.1.1.2 Chemicals and Reagents Used for Biochemical Tests	32
3.1.1.3 Chemicals and Reagents Used for Histochemical Stains	33
3.1.1.4 Chemicals and Reagents Used for Immunohistochemistry ...	34
3.1.1.5 Chemicals and Reagents Used for RNA Purification and RT-PCR Assay	34
3.1.2 Equipment and Instruments.....	35
3.1.2.1 Equipment and Instruments Used for Sample Collection and Storage	35
3.1.2.2 Equipment and Instruments Used for Biochemical Tests	36
3.1.2.3 Equipment and Instruments Used for Tissue Processing and Histochemical Stains	36
3.1.2.4 Equipment and Instruments Used for Immunohistochemistry	37
3.1.2.5 Equipment and Instruments Used for RNA Purification and RT-PCR Assay	37
3.2 Study Design.....	38
3.3 Sample Size	40
3.4 Ethical Approval	40
3.5 Experimental Design	40
3.6 Specimen Collection and Processing.....	41
3.7 Serum Biochemical Analysis.....	42
3.7.1 Determination of Serum Creatinine	42
3.7.1.1 Principle.....	42
3.7.1.2 Procedure	43
3.7.2 Determination of Serum Urea	43
3.7.2.1 Principle.....	43
3.7.2.2 Procedure	44
3.7.3 Determination of Serum Cystatin C.....	44
3.7.3.1 Principle.....	44
3.7.3.2 Procedure	45
3.7.4 Determination of Serum Uric Acid	47
3.7.4.1 Principle.....	47
3.7.4.2 Procedure	48
3.7.5 Determination of Serum Sodium, Potassium and Chloride	48
3.7.5.1 Principle.....	48
3.7.5.2 Procedure	49
3.7.6 Determination of Serum Calcium	49
3.7.6.1 Principle.....	49
3.7.6.2 Procedure	50
3.7.7 Determination of Serum Phosphate	50
3.7.7.1 Principle.....	50
3.7.7.2 Procedure	51
3.7.8 Determination of Serum Glucose.....	51
3.7.8.1 Principle.....	51
3.7.8.2 Procedure	52

3.7.9 Determination of Serum Advanced Glycation End-Products	52
3.7.9.1 Principle.....	52
3.7.9.2 Procedure.....	52
3.7.10 Determination of Membrane Lipid Peroxidation.....	55
3.7.10.1 Principle.....	55
3.7.10.2 Procedure.....	56
3.7.11 Determination of Serum Acetylcholinesterase (AChE).....	58
3.7.11.1 Principle.....	58
3.7.11.2 Procedure.....	59
3.8 Histology	61
3.8.1 Tissue Processing.....	61
3.8.1.1 Fixation.....	62
3.8.1.2 Dehydration	62
3.8.1.3 Clearing	62
3.8.1.4 Infiltration, Embedding and Sectioning	63
3.8.2 Haematoxylin and Eosin Stain.....	63
3.8.2.1 Principle.....	63
3.8.2.2 Procedure.....	64
3.8.3 Periodic acid Schiff Stain.....	65
3.8.3.1 Principle.....	65
3.8.3.2 Procedure.....	66
3.8.4 Masson's Trichrome Stain	68
3.8.4.1 Principle.....	68
3.8.4.2 Procedure.....	68
3.9 Immunohistochemistry	71
3.9.1 Principle	71
3.9.2 Procedure.....	72
3.10 Real-time PCR.....	75
3.10.1 RNA stabilization.....	76
3.10.1.1 Principle.....	76
3.10.1.2 Procedure.....	76
3.10.2 RNA purification.....	76
3.10.2.1 Principle.....	76
3.10.2.2 Procedure.....	76
3.10.3 RNA purity.....	78
3.10.3.1 Principle.....	78
3.10.3.2 Procedure.....	79
3.10.4 RNA integrity.....	79
3.10.4.1 Principle.....	79
3.10.4.2 Procedure.....	79
3.10.5 First-strand cDNA synthesis	80
3.10.5.1 Principle.....	80
3.10.5.2 Procedure.....	80
3.10.6 Real-time PCR for RT ² Profiler PCR Array	81
3.10.6.1 Principle.....	81
3.10.6.2 Selection of genes for expression study	84
3.10.6.3 Procedure.....	85
3.10.6.4 Genes expression analysis using RT ² profiler PCR arrays..	86
3.11 Statistical analysis.....	87

CHAPTER FOUR: RESULTS	88
4.1 Physical observations of rats exposed to CPF	88
4.2 Biochemical Results	88
4.2.1 Acetylcholinesterase activity	88
4.2.2 Renal Biochemical Markers	89
4.2.3 Serum Glucose and Advanced Glycation End-products	90
4.2.4 Serum Malondialdehyde Level	90
4.3 Histopathology Findings.....	91
4.3.1 Overview of the histological examination	91
4.3.2 Histology of rat kidney in control and vehicle groups.....	94
4.3.3 Histology of rat kidney in CPF-exposed group.....	97
4.4 Immunohistochemistry Findings	100
4.5 mRNA Expression of Selected Genes	104
CHAPTER FIVE: DISCUSSION	107
5.1 AChE activity	108
5.2 Renal function.....	108
5.3 Histopathological changes in kidney	110
5.4 Postulated mechanism of chronic low dose of CPF induced nephrotoxicity	112
5.4.1 Hyperglycaemia	112
5.4.2 Advanced Glycation End-products	113
5.4.3 Malondialdehyde.....	114
5.4.4 Expression of selected genes involved in hyperglycaemia, oxidative stress and cell death pathway	115
CHAPTER SIX: CONCLUSION	117
REFERENCES	118

LIST OF TABLES

Table 3.1	Preparation of cystatin C standards	46
Table 3.2	Preparation of advanced glycation end-products standards	53
Table 3.3	Preparation of malondialdehyde standards	57
Table 3.4	Preparation of acetylcholinesterase standards	60
Table 3.5	Procedure of tissue processing	62
Table 3.6	The Protocol of Haematoxylin and Eosin stain	64
Table 3.7	The Protocol of Periodic acid Schiff Stain	66
Table 3.8	The Protocol of Masson's Trichrome stain	69
Table 3.9	The Protocol of Immunohistochemistry Staining	72
Table 3.10	RNA sample mixed with RNase-free water to prepare genomic DNA elimination mix	81
Table 3.11	Selected genes and their functions	85
Table 3.12	Cycling conditions for Bio-Rad cycler	86
Table 4.1	Comparison of serum acetylcholinesterase activity between CPF and control groups	88
Table 4.2	Comparison of renal biochemical markers between CPF and control groups	89
Table 4.3	Comparison of serum glucose and advanced glycation end-products between CPF and control groups	90
Table 4.4	Comparison of serum malondialdehyde between CPF and control groups	91
Table 4.5	Selected genes expression chronic CPF-exposed kidneys	105

LIST OF FIGURES

Figure 2.1	Metabolism of chlorpyrifos and its metabolites, adapted from (Timchalk, 2006)	8
Figure 2.2	Chemical structure of chlorpyrifos (PubChem)	9
Figure 2.3	The interaction of chlorpyrifos (CPF) and acetylcholinesterase (AChE) (Timchalk, 2006)	9
Figure 2.4	Reactivation of acetylcholinesterase (AChE) by hydrolysis (Gupta & Milatovic, 2012; Timchalk, 2006)	9
Figure 2.5	Reactivation of acetylcholinesterase (AChE) by oxime (Morris et al., 2014).	10
Figure 2.6	Irreversible inhibition (ageing) of acetylcholinesterase (AChE) (Gupta & Milatovic, 2012; Timchalk, 2006).	10
Figure 2.7	Aldose reductase and polyol pathway, adapted from (Brownlee, 2001).	23
Figure 2.8	Glutathione (GSH) neutralize hydrogen peroxide (H ₂ O ₂) and hydroperoxides (ROOH) (Aoyama & Nakaki, 2012).	24
Figure 2.9	Formation of advanced glycation end products (AGEs): the Maillard reaction, glucose autooxidation, lipid peroxidation and through the polyol pathway adapted from (Luevano-Contreras & Chapman-Novakofski, 2010; Singh et al., 2014).	25
Figure 2.10	Redox Reaction. Formation of reactive intermediates from molecular oxygen and actions of antioxidant enzymes (Kumar et al., 2015).	27
Figure 2.11	Mechanism of cell injury adapted from (Kumar et al., 2015).	30
Figure 2.12	The present study hypothesized that oxidative damage to kidney is secondary to hyperglycaemia and AGEs formation, leading to kidney dysfunction and kidney histopathological changes.	31
Figure 3.1	The flow chart of the study	39
Figure 3.2	The principle of the kinetic colorimetric assay to determine creatinine	42

Figure 3.3	The principle of the enzymatic assay to determine urea.	44
Figure 3.4	Preparation of cystatin C standards.	45
Figure 3.5	Standard curve of cystatin C.	47
Figure 3.6	The principle of uric acid assay.	48
Figure 3.7	The principle of calcium assay.	50
Figure 3.8	The principle of phosphate assay.	50
Figure 3.9	The principle of hexokinase method.	51
Figure 3.10	Preparation of advanced glycation end-products standards.	53
Figure 3.11	Standard curve of advanced glycation end-products.	55
Figure 3.12	Preparation of malondialdehyde standards.	56
Figure 3.13	Standard curve of malondialdehyde.	58
Figure 3.14	Preparation of acetylcholinesterase standards.	59
Figure 3.15	Standard curve of acetylcholinesterase.	61
Figure 3.16	The principle of two-steps immunohistochemistry staining technique using horseradish peroxidase (HRP) (Suvarna et al., 2019).	71
Figure 3.17	Use of SYBR Green I to detect accumulating amplicons in real-time quantitative PCR. SYBR Green I shows a large increase in fluorescence on binding to the double-stranded amplicon. Fd, fluorescent dye (Sugden & Winter, 2008)	83
Figure 4.1	Histology slides were viewed by image analyser. A: H&E, X20, B: periodic acid-Schiff stain, X20, C: Masson's trichrome stain, X20.	91
Figure 4.2	A: normal rat liver, positive control of periodic acid-Schiff (PAS) stain. Positive PAS stain showed magenta colour in hepatocyte cytoplasm. B: acute appendicitis (human), positive control of Masson's trichrome stain. Fibrous collagen stained blue colour and nuclei stained blue-black colour.	93
Figure 4.3	Histology of control group. Normal histology of glomerulus, tubules and interstitium. Hypostatic congestion in a few areas (black arrow). A: H&E stain, X400. B: periodic acid-Schiff stain showed magenta colour at the brush border of proximal	

	tubular cells and basement membrane of both glomerulus and tubules, X400. C: Masson's trichrome stain showed no collagen deposition, X400.	95
Figure 4.4	Histology of vehicle group. Normal histology of glomerulus, tubules and interstitium. Hypostatic congestion in a few areas (black arrow). A: H&E stain, X400. B: periodic acid-Schiff stain showed magenta colour at the brush border of proximal tubular cells and basement membrane of both glomerulus and tubules, X400. C: Masson's trichrome stain showed no collagen deposition, X400.	96
Figure 4.5	Histopathological changes of CPF-exposed kidney (Group 3). H&E stain, X100.	97
Figure 4.6	Histopathological changes of CPF-exposed kidney (Group 3) showed global glomerular hypercellularity (green arrow). A: H&E stain, X400. B: periodic acid-Schiff stain, X400. C: Masson's trichrome stain, X400.	98
Figure 4.7	Histopathological changes of CPF-exposed kidney (Group 3) showed global glomerular hypercellularity (green arrow). Separation of proximal tubular cells from the basement membrane, which have lack of brush border (blue arrow). Proximal tubular dilatation (red arrow). No prominent fibrosis in glomeruli, tubules and interstitium. A: H&E stain, X400. B: periodic acid-Schiff stain, X400. C: Masson's trichrome stain, X400.	99
Figure 4.8	Tubular injury of CPF-exposed kidney (Group 3). A: separation of proximal tubular cells from the basement membrane, which have lack of brush border (blue arrow). Vacuolar degeneration of focal proximal tubular cells (yellow arrow). B: proximal tubular dilatation (red arrow). Some distal tubules have eosinophilic tubular casts (black arrow). A and B: H&E stain, X400.	100
Figure 4.9	Immunohistochemical expression of AGEs. A: trace immunostaining intensity of AGEs in the glomeruli of normal renal tissue; B: strong immunostaining intensity of AGEs in mesangial matrix and cell membrane of the glomeruli of CPF-exposed rats; C: atheroma in rat aorta, positive control of AGEs.	101
Figure 4.10	Immunohistochemical expression of MDA. A: trace immunostaining intensity of MDA in the cytoplasm of tubular cells in the normal kidneys; B: strong immunostaining intensity of MDA in the cytoplasm of the tubular cells of	

CPF-exposed rats; C: human adenocarcinoma breast, positive control of MDA	103
Figure 4.11 mRNA expression of selected genes in chronic CPF-exposed kidneys	106
Figure 5.1 NADPH oxidase produce superoxide ($O_2^{\cdot -}$) in renal cortex.	115



LIST OF ABBREVIATIONS

$(\text{NH}_4)_2 \text{MoO}_4$	Ammonium molybdate
$(\text{NH}_4)_3 [\text{PO}_4 (\text{MoO}_3)_{12}]$	Phosphomolybdate complex
ACh	Acetylcholine
AChE	Acetylcholinesterase
Actb	Actin, beta
ADP	Adenosine dinucleotide
<i>Ager</i>	Advanced glycosylation end product-specific receptor
AGEs	Advanced glycation end products
AKI	Acute kidney injury
BuChE	Butyrylcholinesterase
Ca^{2+}	Calcium
<i>Casp3</i>	Caspase 3
<i>Casp8</i>	Caspase 8
<i>Casp9</i>	Caspase 9
<i>Cat</i>	Catalase
CAT	Catalase
<i>Ccl2</i>	Chemokine (C-C motif) ligand 2
Ccl2	Chemokine (C-C motif) ligand 2
CKD	Chronic kidney disease
CPF	Chlorpyrifos
CRF	Chronic renal failure
<i>Cst3</i>	Cystatin C

<i>Cytc</i>	Cytochrome C, somatic
ELISA	Enzyme-linked immunoabsorbent assay
esRAGE	Endogenously secretory RAGE
G6PD	Glucose-6-phosphate dehydrogenase
GFR	Glomerular filtration rate
GITC	Guanidine isothiocyanate
GLDH	Glutamate dehydrogenase
GPX	Glutathione peroxidase
<i>Gpx3</i>	Glutathione peroxidase 3
GR	Glutathione reductase
GSH	Reduced glutathione
<i>Gsr</i>	Glutathione reductase
H&E	Haematoxylin and eosin stain
H ⁺	Hydrogen ions
H ₂ O	Water
H ₂ O ₂	Hydrogen peroxide
<i>Havcr1</i>	Hepatitis A virus cellular receptor 1
Havcr1	Hepatitis A virus cellular receptor 1
HCO ₃	Bicarbonate ions
HK	Hexokinase
HKG	Housekeeping genes
HRP	Horseradish peroxidase
IHC	Immunohistochemistry
IMS	Intermediate syndrome
IQR	Interquartile range

KIM-1	Kidney injury molecule-1
<i>Lcn2</i>	Lipocalin 2
Lcn2	Lipocalin 2
MCP-1	Monocyte chemoattractant protein-1
MDA	Malondialdehyde
Mg ²⁺	Magnesium ions
NAD	Nicotinamide adenine dinucleotide.
NADH	The reduced form of nicotinamide adenine dinucleotide
NADP	Nicotinamide dinucleotide phosphate
NADPH	The reduced form of nicotinamide dinucleotide phosphate
NGAL	Neutrophil gelatinase-associated lipocalin
NH ₄ ⁺	Ammonium
<i>Nos2</i>	Nitric oxide synthase 2, inducible
O ₂	Oxygen
O ₂ [°]	Superoxide
OCPC	O-cresolphthalein complexone
OD	Optical density
OP	Organophosphate
OPIDPN	OP-induced delayed polyneuropathy
PAS	Periodic acid Schiff
Pgk1	Phosphoglycerate kinase 1
PO ₄ ³⁻	Inorganic phosphate
<i>Pon1</i>	Paraoxonase-1
PON-1	Paraoxonase-1
PPE	Personal protective equipment

RAGE	AGEs receptor
RBC	Red blood cell
Ring1	Ring finger protein 1
RIPK-1	Receptor associated kinase-1
<i>Ripk1</i>	Receptor-interacting serine-threonine protein kinase 1
RIPK-3	Receptor associated kinase-3
<i>Ripk3</i>	Receptor-interacting serine-threonine protein kinase 3
RT-PCR	Real time polymerase chain reaction
SOD	Superoxide dismutase
<i>Sod3</i>	Superoxide dismutase 3, extracellular
sRAGE	Secretory RAGE
TCO ₂	Total carbon dioxide
TCP	3,5,6-trichloro-2-pyridinol
TMB	3, 3', 5, 5' tetramethylbenzidine
TNF	Tumour necrosis factor
<i>Tp53</i>	Tumor protein p53

CHAPTER ONE

INTRODUCTION

Organophosphorous (OP) compound is commonly used as a pesticide in the environment, public health and agriculture industry, particularly in developing countries. It is also used as chemical warfare nerve agents, therapeutic drugs, fire retardants, solvents and plasticizers (Balali-Mood, 2014). Due to its widespread use worldwide, OP poisoning was estimated to be between 750,000 to 3,000,000 cases globally per year (Soltaninejad & Shadnia, 2014).

Chlorpyrifos (CPF) is an OP which was first introduced in the U.S in 1965 (Christensen, Harper, Luukinen, Buhl, & Stone, 2009). It is used as insecticide, acaricide, and miticide (Koshlukova & Reed, 2014).

CPF is oxidized by cytochrome P450 in the liver to form CPF-oxon, which is a strong acetylcholinesterase (AChE) inhibitor. CPF-oxon is metabolized by hepatic and extra-hepatic esterases (Eleršek & Filipič, 2011) to form water soluble 3,5,6-trichloro-2-pyridinol (TCP) and diethylphosphate (Timchalk, 2006). Both are excreted in urine (Tang, Rose, & Chambers, 2006).

Although, CPF is classified as moderately hazardous (Class II) pesticide (Organization, 2010), it is widely used in the agrochemical industry in Malaysia (Farina, Abdullah, Bibi, & Khalik, 2016; Ismail, Halimah, Tan, & Tayeb, 2017; Zaidon, Ho, Hashim, Saari, & Praveena, 2018) because of its potency, broad-spectrum activity against a wide range of pests, short residuality on foliar surfaces and moderate residuality in soil, as well as low mammalian toxicity (Science, 2017).

The routes of CPF exposure include inhalation, ingestion, dermal contact and conjunctival route (Christensen et al., 2009). Dermal contact is the main route of entry in agrochemical chemistry (Costa, 2013; Soltaninejad & Shadnia, 2014).

Pest control, agricultural and industrial workers are exposed to low dose of OP throughout their lifetime, mostly through dermal contact (Costa, 2013). Agriculture related OP exposure may involve 25.96 % and 10.67% of all OP exposures in the world and Malaysia, respectively (ILOSTAT, 2019). In Malaysia, Indian has the highest prevalence of pesticide poisoning and death. Due to poor education, many of the farmers are often lack of adequate knowledge on safety practices and use of personal protective equipment (PPE) (Ali & Shaari, 2015; Rajasuriar, Awang, Hashim, & Rahmat, 2007).

The primary target organ for CPF toxicity is the central and peripheral nervous system because the accumulated acetylcholine (ACh) neurotransmitter in nerve endings causing sustained cholinergic hyperstimulation in central and peripheral nervous systems (Eleršek & Filipič, 2011). However, the previous animal studies showed that CPF may also cause tissue damage to literally any tissue, including kidneys (Tripathi & Srivastav, 2010), liver, spleen, lymph node, adrenal gland, epididymis, and testis (Akhtar, Srivastava, & Raizada, 2009).

Epidemiological studies have reported that there is an association between chronic kidney disease (CKD) and long-term occupational exposure to OP (Johnson, Wesseling, & Newman, 2019). However, there is limited evidence of chronic exposure to low dose OP effects on the kidney in animal models.

As CPF is regarded as a neurotoxin, the studies on the effects of subclinical or subthreshold dose of CPF on the nervous system in animal models were done (Rush, Liu, Hjelmhaug, & Lobner, 2010; Speed et al., 2012; Terry et al., 2007). However, the

effects on other major organs, such as the kidneys were not mentioned. Based on few available studies, the possible mechanism of nephrotoxicity in chronic low dose of CPF exposure could be through CPF induction of oxidative damage to the kidney (Heikal, Mossa, Marei, & Rasoul, 2012; Nasr, El-Demerdash, & El-Nagar, 2016). Hence, this study aimed to assess the effects of chronic subcutaneous low dose of CPF exposure on the rat kidneys.

1.1 JUSTIFICATION OF THE STUDY

- i. OPs are widely used in agriculture and agrochemical industry. The incidence of CKD of unknown aetiology increases in agriculture workers who are routinely exposed to low dose OPs throughout their life via dermal contact may give rise to OP-induced nephrotoxicity.
- ii. CPF is widely used as an agrochemical in Malaysia.
- iii. There is limited study on the effects of chronic subcutaneous exposure to low dose CPF on the kidney.
- iv. Understanding the toxic mechanisms for nephrotoxicity provides useful information on the management and prevention of the complications.

1.2 GENERAL OBJECTIVE

To assess the effects of chronic subcutaneous low dose of CPF exposure on the kidney

1.3 SPECIFIC OBJECTIVES

- i. To assess the renal function parameters (urea, creatinine, uric acid, cystatin C and electrolytes) in rats exposed to chronic low dose CPF